PHA121, the first orally available bradykinin B2-receptor antagonist, shows clinically relevant activity in a translational in vivo model

Pharvaris Press release, Uncategorised

Data accepted for presentation at the American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting 2020 Zug, Switzerland, April 9, 2020 – Pharvaris GmbH, a clinical-stage company focused on the discovery and development of novel oral B2-receptor antagonists for the treatment of hereditary angioedema (HAE) and other B2-receptor-mediated indications, announced data from a late-breaking poster planned for presentation at …

Pharvaris Appoints Peng Lu, M.D., Ph.D., as Chief Medical Officer

Pharvaris Press release, Uncategorised

Company strengthens executive team with addition of skilled HAE drug developer Leiden, The Netherlands, Feb. 7, 2020 – Pharvaris B.V., a clinical-stage company focused on the discovery and development of novel oral B2-receptor antagonists for the treatment of hereditary angioedema (HAE) and other B2-receptor-mediated indications, has appointed Peng Lu, M.D., Ph.D., to the newly-created position of Chief Medical Officer, a …

Pharvaris Announces $66 Million Series B Financing to Advance the Clinical Development of an Oral Therapy for Hereditary Angioedema

Pharvaris Press release, Uncategorised

Pharvaris has initiated its first-in-human clinical trial of PHA121 Series B participants led by Foresite Capital with additional new investors Bain Capital Life Sciences, venBio Partners, and Venrock Partners Leiden, The Netherlands, Sept. 10, 2019 – Pharvaris B.V., a clinical-stage company focused on the discovery and development of novel oral B2-receptor antagonists for the treatment of hereditary angioedema (HAE) and …